Haemophilia · 2005 · 13 citations · 9 references
MedicinePediatricsPharmacotherapyHemostasisNeonatologyPediatric HematologyCoagulation DisordersCoagulation Factor DeficienciesHemostatic DisordersPediatric ThrombosisThrombosisThrombotic DisordersIntracranial Hemorrhage In InfantsNeonatal Bleeding DisordersNeonatal HemophiliaPediatric Coagulation DisordersRare Genetic VariantsRecombinant Activated Factor ViiSerious Adverse EventsSubgaleal Hemorrhage
Intracranial (ICH) and extracranial (ECH) haemorrhages are potentially life-threatening events that may occur comorbidly in neonates with haemophilia. There is little data on the use of recombinant factor IX (rFIX; BeneFIX in the neonate. Children <15 years of age are known to require higher doses of recombinant Factor IX (FIX) than older persons, which raises specific concerns in the neonate due to the increased risk of thrombosis in this age group (Thromb Haemost 2002; 87: 431). This report describes a case in which a high rate of continuous infusion of recombinant FIX was used to treat a newborn with significant intracranial and subgaleal haemorrhages. A high rate of infusion maintained at 30-35 U kg(-1) h(-1) was necessary to maintain adequate FIX levels. Despite the high rate of continuous infusion, no adverse events were noted. Our patient had a rare genetic mutation causing severe haemophilia B. A neonate with severe haemophilia B was treated successfully with recombinant FIX through continuous infusion. A high rate of infusion was required and no complications were noted.
9
Gilbert White, Aime Beebe, Brenda Nielsen · Thrombosis and Haemostasis · 1997 · 190 citations
Medicine, Biotechnology, Hematology +14
Clinical evaluation of recombinant factor IX.
G. White, Amy D. Shapiro, Margaret V. Ragni et al. · PubMed · 1998 · 107 citations
Medicine, Hematology, Hemostasis +7